白细胞介素 6 在免疫相关不良反应（irAEs）的非小细胞肺癌（NSCLC）免疫治疗中的作用。
The role of IL-6 in immunotherapy of non-small cell lung cancer (NSCLC) with immune-related adverse events (irAEs).
机构信息
Arrhythmia Center, Fuwai Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China.
Respiratory Medicine Department, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China.
出版信息
Thorac Cancer. 2020 Apr;11(4):835-839. doi: 10.1111/1759-7714.13341. Epub 2020 Feb 11.
Abstract
IL-6 is a cytokine that plays an important role in response to injury or infection and is a promising biomarker for predicting poor prognosis and therapeutic targets in non-small cell lung cancer (NSCLC). This article reviews the biochemical mechanism, function and genotype of IL-6, and summarizes the diagnostic and prognostic value of IL-6 level. Anti-IL-6 therapy does not affect the effect of immunocheckpoint inhibitors (ICIs), but enhances its anticancer function, which may be the treatment option for immune-related adverse events (irAEs) in the future. Therefore, IL-6 may be a therapeutic target for the treatment of NSCLC.
摘要
白细胞介素 6（IL-6）是一种细胞因子，在应对损伤或感染时发挥着重要作用，是预测非小细胞肺癌（NSCLC）不良预后和治疗靶点的有前途的生物标志物。本文综述了 IL-6 的生化机制、功能和基因型，并总结了 IL-6 水平的诊断和预后价值。抗 IL-6 治疗并不影响免疫检查点抑制剂（ICIs）的疗效，但增强了其抗癌功能，这可能是未来治疗免疫相关不良反应（irAEs）的选择。因此，IL-6 可能是治疗 NSCLC 的治疗靶点。
相似文献
1
The role of IL-6 in immunotherapy of non-small cell lung cancer (NSCLC) with immune-related adverse events (irAEs).
Thorac Cancer. 2020 Apr;11(4):835-839. doi: 10.1111/1759-7714.13341. Epub 2020 Feb 11.
2
Peripheral Blood Markers Identify Risk of Immune-Related Toxicity in Advanced Non-Small Cell Lung Cancer Treated with Immune-Checkpoint Inhibitors.
Oncologist. 2019 Aug;24(8):1128-1136. doi: 10.1634/theoncologist.2018-0563. Epub 2019 Apr 23.
3
Association Between Immune-related Adverse Events and Efficacy of Immune Checkpoint Inhibitors in Non-small-cell Lung Cancer.
Clin Lung Cancer. 2019 May;20(3):201-207. doi: 10.1016/j.cllc.2018.10.002. Epub 2018 Oct 11.
4
The Role of Immune-Related Adverse Events in Prognosis and Efficacy Prediction for Patients with Non-Small Cell Lung Cancer Treated with Immunotherapy: A Retrospective Clinical Analysis.
Oncology. 2021;99(5):271-279. doi: 10.1159/000511999. Epub 2021 Feb 25.
5
Discontinuation due to immune-related adverse events is a possible predictive factor for immune checkpoint inhibitors in patients with non-small cell lung cancer.
Thorac Cancer. 2019 Sep;10(9):1798-1804. doi: 10.1111/1759-7714.13149. Epub 2019 Jul 22.
6
Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis.
J Cancer Res Clin Oncol. 2019 Feb;145(2):479-485. doi: 10.1007/s00432-018-2805-3. Epub 2018 Dec 1.
7
Immunotherapy as second-line treatment and beyond for non-small cell lung cancer in a single center of China: Outcomes, toxicities, and clinical predictive factors from a real-world retrospective analysis.
Thorac Cancer. 2020 Jul;11(7):1955-1962. doi: 10.1111/1759-7714.13488. Epub 2020 May 29.
8
Profiling Preexisting Antibodies in Patients Treated With Anti-PD-1 Therapy for Advanced Non-Small Cell Lung Cancer.
JAMA Oncol. 2019 Mar 1;5(3):376-383. doi: 10.1001/jamaoncol.2018.5860.
9
Opportunistic infections complicating immunotherapy for non-small cell lung cancer.
Thorac Cancer. 2020 Jun;11(6):1689-1694. doi: 10.1111/1759-7714.13422. Epub 2020 Apr 20.
10
Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab.
Lung Cancer. 2018 Jan;115:71-74. doi: 10.1016/j.lungcan.2017.11.019. Epub 2017 Nov 21.
引用本文的文献
1
Adoptive cell therapy for cancer: combination strategies and biomarkers.
Front Immunol. 2025 Aug 1;16:1603792. doi: 10.3389/fimmu.2025.1603792. eCollection 2025.
2
DNA Damage and Inflammatory Response of p53 Null H358 Non-Small Cell Lung Cancer Cells to X-Ray Exposure Under Chronic Hypoxia.
Int J Mol Sci. 2024 Nov 23;25(23):12590. doi: 10.3390/ijms252312590.
3
The Distinct Biological Effects of 6-Hydroxy-L-Nicotine in Representative Cancer Cell Lines.
Molecules. 2024 Nov 26;29(23):5593. doi: 10.3390/molecules29235593.
4
Circulating Interleukins as Biomarkers in Non-Small Cell Lung Cancer Patients: A Pilot Study Compared to Normal Individuals.
Diseases. 2024 Sep 18;12(9):221. doi: 10.3390/diseases12090221.
5
DOX-PLGA Nanoparticles Effectively Suppressed the Expression of Pro-Inflammatory Cytokines TNF-a, IL-6, iNOS, and IL-1β in MCF-7 Breast Cancer Cell Line.
Rep Biochem Mol Biol. 2024 Jan;12(4):530-539. doi: 10.61186/rbmb.12.4.530.
6
Advancing non-small cell lung cancer treatment: the power of combination immunotherapies.
Front Immunol. 2024 Jul 2;15:1349502. doi: 10.3389/fimmu.2024.1349502. eCollection 2024.
7
NF-κB in the Radiation Response of A549 Non-Small Cell Lung Cancer Cells to X-rays and Carbon Ions under Hypoxia.
Int J Mol Sci. 2024 Apr 19;25(8):4495. doi: 10.3390/ijms25084495.
8
Inhibition of IL-25/IL-17RA improves immune-related adverse events of checkpoint inhibitors and reveals antitumor activity.
J Immunother Cancer. 2024 Mar 21;12(3):e008482. doi: 10.1136/jitc-2023-008482.
9
Impact of IL-6 and IL-1β Gene Variants on Non-small-cell Lung Cancer Risk in Egyptian Patients.
Biochem Genet. 2024 Oct;62(5):3367-3388. doi: 10.1007/s10528-023-10596-2. Epub 2023 Dec 16.
10
Exploring the interplay between with the expression of microRNA, and inflammatory mediators in colorectal cancer.
Front Microbiol. 2023 Nov 23;14:1302719. doi: 10.3389/fmicb.2023.1302719. eCollection 2023.
本文引用的文献
1
Management of Immunotherapy-Related Toxicities, Version 1.2019.
J Natl Compr Canc Netw. 2019 Mar 1;17(3):255-289. doi: 10.6004/jnccn.2019.0013.
2
New therapeutic perspectives to manage refractory immune checkpoint-related toxicities.
Lancet Oncol. 2019 Jan;20(1):e54-e64. doi: 10.1016/S1470-2045(18)30828-3.
3
A severe case of refractory esophageal stenosis induced by nivolumab and responding to tocilizumab therapy.
J Immunother Cancer. 2018 Dec 27;6(1):156. doi: 10.1186/s40425-018-0481-0.
4
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
CA Cancer J Clin. 2018 Nov;68(6):394-424. doi: 10.3322/caac.21492. Epub 2018 Sep 12.
5
Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade.
J Oncol Pharm Pract. 2019 Apr;25(3):551-557. doi: 10.1177/1078155217745144. Epub 2017 Dec 5.
6
Predicting response and toxicity to immune checkpoint inhibitors using routinely available blood and clinical markers.
Br J Cancer. 2017 Sep 26;117(7):913-920. doi: 10.1038/bjc.2017.274. Epub 2017 Aug 24.
7
Beneficial effect of tocilizumab in myasthenia gravis refractory to rituximab.
Neuromuscul Disord. 2017 Jun;27(6):565-568. doi: 10.1016/j.nmd.2017.03.007. Epub 2017 Mar 16.
8
Generation of dendritic cell-based vaccine using high hydrostatic pressure for non-small cell lung cancer immunotherapy.
PLoS One. 2017 Feb 10;12(2):e0171539. doi: 10.1371/journal.pone.0171539. eCollection 2017.
9
Immune-based Therapies for Non-small Cell Lung Cancer.
Anticancer Res. 2017 Feb;37(2):377-387. doi: 10.21873/anticanres.11330.
10
Quality of Life in Patients With Advanced Cancer: Differential Association With Performance Status and Systemic Inflammatory Response.
J Clin Oncol. 2016 Aug 10;34(23):2769-75. doi: 10.1200/JCO.2015.65.7742. Epub 2016 Jun 27.
Zotero 插件